Vorasidenib (Voranigo)

Medicine at a glance

Vorasidenib is an oral targeted medicine. Its verified brand is Voranigo. It blocks altered IDH1 and IDH2 proteins in selected brain tumours. The team tests tumour tissue for a suitable gene change before considering treatment. It is taken once daily, usually over an extended period while it is helping and remains tolerable.

The main medicine-specific safety concern is liver injury. Blood tests are needed even if you feel well: every two weeks initially, then monthly over the first two years, with further monitoring afterwards. Severe liver problems can occur, so keeping these appointments is part of treatment.

Food instructions, some age and weight requirements, and contraception intervals differ between prescribing regions. Your own prescription and supplied leaflet must guide you. Do not combine instructions from different packs or change the schedule yourself.

What vorasidenib is and how it works

IDH stands for isocitrate dehydrogenase. IDH1 and IDH2 are enzymes: proteins that help chemical processes take place inside cells. Particular changes, or mutations, can make these enzymes produce too much of a substance called 2-hydroxyglutarate, often shortened to 2-HG. This can interfere with normal cell development and contribute to tumour growth.

Vorasidenib is a small-molecule inhibitor designed to reach brain tumour tissue and block the altered enzymes. Reducing abnormal 2-HG production can help slow tumour growth. It is targeted therapy rather than conventional chemotherapy or checkpoint immunotherapy. Having a specific target does not make treatment risk-free.

The aim may be to keep the tumour controlled and postpone the need for another treatment. A stable scan can therefore be meaningful even when there is no obvious shrinkage. Treatment cannot guarantee a particular outcome, and regular assessments remain essential. Your specialist will explain what benefit would look like in your situation.

How the team decides whether it is suitable

The specialist considers the tumour's diagnosis, grade, molecular results, appearance on MRI, previous surgery and other treatment, symptoms and overall health. An appropriate IDH1 or IDH2 result is necessary but is not the whole decision. European information specifically refers to IDH1 R132 or IDH2 R172 changes. A mutation found in a different disease does not automatically make this treatment appropriate.

The team also considers how urgently other treatment is needed. Vorasidenib should not become a reason to postpone treatment that your specialist believes is necessary now. This decision is individual and should include your priorities, anticipated benefits, monitoring burden and possible harms.

Treatment can be considered from age 12 in the appropriate setting, but product instructions differ by weight. US information provides a lower dose for adolescents weighing under 40 kg; European information does not recommend use below 40 kg because of insufficient data. Safety and effectiveness below age 12 are not established. An adolescent needs a specialist plan rather than an adult's tablets adjusted at home.

Before treatment starts

Tell the team about liver disease, abnormal liver tests, kidney problems, dialysis, seizures, allergies and all medicines you take. Include tobacco smoking, alcohol, herbal products, vitamins and supplements. Provide the names and doses of anti-seizure medicines; several need particular interaction checks.

Baseline blood tests include liver tests and other blood chemistry. Blood counts and kidney function help establish a starting point. A pregnancy test is needed for someone who could become pregnant. Discuss fertility preservation before the first dose if having children in the future matters to you.

Reduced kidney function requires a specific assessment. European information says vorasidenib should not be used when the estimated filtration rate, or eGFR, is 40 mL/min/1.73 m² or lower, or during dialysis. US information uses a different measurement, creatinine clearance: at 40 mL/min or lower, or during dialysis, it describes an unstudied population requiring closer monitoring and adjustment for toxicity. These measurements and instructions are not interchangeable; your team must interpret the result. Severe liver impairment is also insufficiently studied and needs particular caution.

The tablets contain lactose. Tell the pharmacist if you have a diagnosed inherited sugar-processing disorder, especially galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. These are different from simply avoiding dairy foods.

Before leaving, make sure you understand the daily dose, food rule, first blood-test dates, missed-dose plan and urgent-contact arrangements. A caregiver can help with reminders and noticing changes, with your permission.

How to take vorasidenib

Dose and routine

The usual adult dose is 40 mg once daily. The US adolescent dose is 40 mg daily at 40 kg or above and 20 mg daily below 40 kg. European dosing is 40 mg daily for eligible patients weighing at least 40 kg. These are starting examples, not instructions to choose your own dose.

Tablets come in 10 mg and 40 mg strengths. For example, a prescribed 20 mg dose uses two 10 mg tablets; do not halve a 40 mg tablet. The team may pause treatment or reduce it to manage side effects. A lower dose can be a planned safety measure, not evidence that treatment has failed.

Take the dose at about the same time daily. Swallow tablets whole with water. Do not split, crush or chew them. There is no routine home-made liquid or feeding-tube method in the current labels. If swallowing is difficult, contact the pharmacist before altering a tablet.

Food instructions

US prescribing information allows vorasidenib with or without food. European information requires an empty stomach: no food for at least two hours before and one hour afterwards. Food changes medicine exposure, so follow the instructions for your supplied product and ask the pharmacist to resolve any conflicting advice. Do not alternate between regional rules.

A daily alarm can help you coordinate the dose, meals and other medicines. If another medicine has its own food requirements, ask for a practical timetable rather than skipping it.

Missed doses, vomiting and extra tablets

If you remember a missed dose less than six hours late, take it promptly, then return to the usual time. If it is more than six hours late, skip it. At exactly six hours, follow the written plan supplied by your pharmacist: professional and patient sections are not worded identically at that boundary. Never double a dose.

If you vomit after taking vorasidenib, do not take replacement tablets. Take the next dose at the usual time the following day. Repeated vomiting needs advice because it can cause dehydration and disrupt other essential medicines. If you take too much, contact the team or urgent medical service immediately, even if you feel well.

Storage and handling

Keep tablets in their labelled bottle, safely away from children. Leave the drying canisters in place and never swallow them. US storage is normally 20–25°C (68–77°F), with permitted brief excursions to 15–30°C (59–86°F); the European product has no special storage conditions. Follow the actual pack and avoid excessive heat or moisture. Return unwanted tablets through the pharmacy's disposal arrangements.

Monitoring and checking whether treatment is working

Liver and other blood tests

Liver monitoring includes enzymes such as ALT, AST and GGT, together with bilirubin; US information also explicitly includes alkaline phosphatase. These tests can detect injury before symptoms appear. The standard schedule is before treatment, every two weeks for the first two months, then monthly for the first two years, followed by testing as clinically needed. European information applies the same early schedule to blood counts and blood chemistry more broadly.

An abnormal result may mean repeat tests weekly or more often, a treatment pause, a lower dose or permanent discontinuation. The decision depends on the pattern and severity, symptoms, possible alternative causes and previous episodes. Do not restart after a liver-related pause until the team confirms the plan.

Other results can include changes in platelets, white blood cells, glucose, phosphate and kidney measurements. The team selects any additional checks according to your results, other medicines and symptoms. If you miss a blood appointment, contact the team promptly to rearrange it and clarify treatment instructions.

Scans, symptoms and daily functioning

MRI scans, neurological assessments and discussion of daily life show whether treatment is helping. There is no single scan timetable suitable for everyone. Keep a short record of seizures, headaches, balance, speech or memory changes and their timing. A caregiver's observations can help, especially when a change is difficult for you to notice. Report new symptoms between visits rather than waiting for the next scan.

Common side effects and practical management

Tiredness and reduced energy

Fatigue may affect work, school and concentration. Plan demanding activities for your better times, use short rests and keep gentle activity within your ability. Ask for help if fatigue is worsening or limiting basic activities. Marked new exhaustion with dark urine, poor appetite or abdominal pain could be liver-related and needs immediate contact.

Diarrhoea, nausea and appetite changes

Keep track of bowel changes and contact the team if diarrhoea persists or becomes troublesome. Replace fluid losses with regular drinks unless you have a prescribed fluid restriction. Small meals may be easier when nauseated, while still respecting your product's fasting window. Only use anti-sickness or anti-diarrhoeal medicines that have been checked with your treatment.

Seek urgent advice for inability to keep fluids down, dizziness on standing, much less urine, blood in stools or severe abdominal pain. Do not assume every abdominal symptom is an ordinary digestive side effect: pain beneath the right ribs may signal liver injury.

Headache, dizziness and aches

Headache, muscle or joint discomfort and dizziness have been reported. Tell the team about persistent or changing symptoms. Ask which pain medicine is suitable, because liver tests and interactions may affect the choice. Avoid driving, heights or machinery when dizzy. Sudden severe headache, new weakness, speech difficulty or a change in awareness needs emergency assessment.

Hair loss is not a prominent common effect in the current prescribing information. Individual experiences can differ; mention unexpected hair or skin changes rather than assuming they are unrelated or stopping treatment yourself.

Important risks that need medical assessment

Liver injury

Vorasidenib can cause more than a mild blood-test change. Serious inflammation, including autoimmune hepatitis where the immune system attacks the liver, liver-cell damage and liver failure have been reported. Current information also includes acute hepatitis after marketing.

Contact the urgent service immediately for yellow eyes or skin, tea-coloured urine, pain in the upper right abdomen, unusual tiredness, loss of appetite or persistent nausea. Significant confusion, extreme drowsiness, collapse or major bleeding warrants emergency care. For these serious liver-warning symptoms, stop taking the tablets and obtain immediate medical advice before any further dose, as directed in the European leaflet. The team will assess whether treatment can safely restart; do not restart it yourself.

Do not rely on the absence of symptoms or a previously normal result. Liver abnormalities can arise beyond the first weeks. Avoid starting liver supplements or “detox” products; they can complicate the assessment and may themselves be harmful.

Seizures and other neurological changes

Seizures were reported during vorasidenib studies, but brain tumours themselves can cause seizures; a seizure does not establish that the medicine caused it. Maintain your prescribed anti-seizure treatment and agreed rescue plan. Do not abruptly stop those medicines because of an interaction concern. The specialist can arrange a safer change where needed.

A new seizure or a change from your usual pattern needs urgent assessment. Caregivers should know the rescue plan, protect the person from injury and time the episode. Emergency situations are described below.

Blood-count and metabolic changes

A fall in platelets may cause unexpected bruising, gum bleeding or nosebleeds. White-cell reductions can affect infection risk. Report fever, shaking chills or feeling suddenly very unwell, including when the temperature is not high. Severe or persistent bleeding needs urgent care. Routine preventive antibiotics are not automatically required for everyone.

Higher glucose can cause unusual thirst and frequent urination; low phosphate may contribute to weakness. Blood tests help identify these problems, and treatment depends on the result. Do not start mineral supplements or change diabetes medicines independently.

Longer-term uncertainty

Long-term safety experience is still developing. European information describes a potential cancer risk suggested by animal findings; this has not established that vorasidenib causes a new cancer in people. The uncertainty is a reason for ongoing follow-up and reporting unexpected persistent symptoms, not a prediction about an individual patient's future.

Other medicines, supplements and vaccines

A liver enzyme called CYP1A2 helps clear vorasidenib. Medicines that slow it down can raise exposure; those that speed it up can reduce treatment effect. Examples needing review include ciprofloxacin, fluvoxamine, rifampicin and phenytoin. US information advises avoiding strong and moderate CYP1A2 inhibitors and moderate inducers; European wording distinguishes strong inhibitors and consideration of alternatives to moderate inducers.

Vorasidenib can also reduce the effectiveness of other medicines. European information flags several anti-seizure drugs, warfarin, certain transplant medicines and other treatments whose blood levels need to remain tightly controlled. It also advises caution with rosuvastatin. Bring a complete list to every prescriber, including a dentist or emergency clinician. Do not stop essential medicines without a supervised replacement plan.

Avoid smoking tobacco because it can lower vorasidenib exposure. Tell the team if you smoke or change your smoking habits and request cessation support. Have cessation medicines checked too; do not assume an over-the-counter or herbal product is interaction-free.

Hormonal contraception may work less reliably; see the reproductive section. Omeprazole did not cause a clinically important change in vorasidenib exposure in the available study, so a blanket ban on acid-reducing medicines is not appropriate. Each medicine still needs checking.

Discuss vaccinations with the team using your blood counts, other treatments and vaccine type. There is no single vorasidenib-label rule requiring every patient to avoid all vaccines or follow the same long post-treatment restriction.

Everyday life during treatment

Regular meals, suitable fluids, sleep and manageable activity can support daily functioning. Ask about alcohol, particularly if liver tests are abnormal; avoid drinking until the team has clarified what is appropriate. Treatment does not require a special “anti-cancer” diet, and restrictive diets can make eating harder.

Work or education may remain possible with adjustments. Written reminders, shorter sessions, rest breaks and help with appointments can be useful when fatigue or concentration problems interfere. Request occupational therapy or neurological rehabilitation if ordinary tasks become difficult. Support for emotional distress is also part of care.

The European leaflet says vorasidenib itself is not expected to impair driving, but your brain tumour, seizures, dizziness and other medicines may do so. Do not interpret the leaflet as permission to drive. Obtain individual medical advice and follow your local licensing rules.

Before travel, coordinate blood tests and prescriptions, carry the medicine in its original pack and keep a written medication list. Ask how to handle time-zone changes without taking doses too close together. Tell dental and surgical teams about vorasidenib; any pause should be planned by the treating clinicians rather than based on a generic rule.

Pregnancy, contraception, fertility and breastfeeding

Vorasidenib may harm an unborn baby. Have pregnancy status checked before starting and tell the team immediately if you or your partner becomes pregnant or pregnancy is suspected. Do not assume reduced fertility prevents pregnancy.

US information requires effective nonhormonal contraception for patients who could become pregnant during treatment and for three months afterwards. Male patients with partners who could become pregnant should also use effective contraception during treatment and for three months after the last dose.

European information specifies effective contraception for both groups during treatment and for at least two months afterwards. Because hormonal methods may become less reliable, it recommends an additional barrier method. Your team must confirm the methods and stop date appropriate to your product and other medicines; do not select the shorter interval yourself.

Do not breastfeed during treatment or for at least two months after the last dose. Whether the medicine enters human milk is unknown.

Animal findings suggest possible effects on male and female fertility, but the extent and reversibility in people are uncertain. Discuss sperm, egg or other appropriate preservation options before starting. Adolescents should have age-appropriate counselling and privacy alongside family support.

After a pause or when treatment finishes

A pause may allow liver results or other effects to recover. Keep the follow-up tests even while tablets are stopped and obtain a clear restart instruction. Do not use leftover tablets to restart independently. Ongoing symptoms may need treatment after the last dose.

Continue contraception and breastfeeding precautions for the instructed interval. Tell other prescribers when vorasidenib stopped because medication plans may need reassessment. Return unused medicine safely. Brain-tumour follow-up, scans, seizure care and rehabilitation continue according to your individual plan; completing tablets does not end those needs.

Frequently asked questions